Variable | A1ATD cohort (n = 540) | Usual COPD cohort (n = 316) | p | |
---|---|---|---|---|
Age | 53.9 (45.0–60.9) | 68.8 (61.5–75.1) | <0.001 | |
Sex | Male n = 311 (57.6 %) | Male n = 182 (57.6 %) | 0.999 | |
Female n = 229 (42.4 %) | Female n = 134 (42.4 %) | |||
Pack years | 11.6 (0.0–24.0) | 44.1 (29.5–62.2) | <0.001 | |
FEV1 (% predicted) | 50.7 (35.1–85.1) | 46.4 (35.0–61.0) | <0.001 | |
KCO (% predicted) | 62.3 (49.3–77.0) | 59 (47.5–77.0) | 0.533 | |
Chronic bronchitis | 185 (34.3 %) | 198 (62.7 %) | <0.001 | |
Emphysema | 358 (66.3 %) | 257 (81.3 %) | 0.002 | |
Bronchiectasis | 142 (26.3 %) | 96 (30.3 %) | 0.678 | |
Frequent exacerbator | 129 (40.8 %) | 193 (61.1 %) | <0.001 | |
eGFR | 81.3 (70.6–93.9) | 85.8 (69.7–101.1) | 0.063 | |
CKD stage | 0.002 | |||
1 | eGFR ≥ 90 | 156 (28.9 %) | 119 (37.6 %) | |
2 | eGFR 60–89 | 279 (51.7 %) | 130 (41.1 %) | |
3 | eGFR 30–59 | 41 (7.6 %) | 35 (11.1 %) | |
4 | eGFR 15–29 | 2 (0.4 %) | 4 (1.3 %) | |
5 | eGFR < 15 | 1 (0.2 %) | 0 (0 %) | |
Unknown (no eGFR) | 61 (11.3 %) | 28 (8.9 %) | ||
cFLC (mg/L) | 25.7 (21.1–31.7) | 31.9 (24.0–43.3) | <0.001 | |
κ/λ | 0.86 (0.71–1.08) | 0.86 (0.72–1.06) | 0.967 |